To Observe the Clinical Effect of Daglizin on Valvular Heart Failure Patients
Gao Junjie
Li Runjun
Zhang Lifang
Tang Xiuying
Abstract：Objective To study the therapeutic effect of daglizin in patients with valvular heart failure.Methods 97 patients with valvular heart failure who were treated in the Department of Cardiology of the First Hospital of Qinhuangdao City from January 2020 to January 2022 were selected as the study objects.The patients were divided into control group(n=41)and observation group(n=56)by random way.The control group was given routine primary treatment such as angiotensin-converting enzyme inhibitors,diuretics and[3-blockers.The observation group was additionally given dagaglizin(10 mg each time,once a day,orally administered)on the basis of the control group.After 3 months of treatment,compared the cardiac functional indexes such as left ventricular ejection fraction(LVEF)、left ventricular end-systolic diameter(LVESD)and left ventricular end-diastolic diameter(LVEDD),and the cardiac function marker N-terminal pro-B-type natriuretic peptide(NT-proBNP),cardiac inflammatory marker high-sensitivity C-reactive protein(hs-CRP)and the score of heart failure quality of Life questionnaire(MLHFQ)were recorded.Results Compared with before treatment,both groups of patients showed an increase in left ventricular ejection fraction after treatment,and the observation group was higher than the control group,with a statistically significant difference(P＜0.05);compared with before treatment,both groups of patients showed a decrease in left ventricular end systolic diameter(LVESD)and left ventricular end diastolic diameter(LVEDD)after treatment,and the observation group was lower than the control group,with a statistically significant difference(P＜0.05).Compared with before treatment,the levels of N-terminal B-type natriuretic peptide precursor(NT-proBNP),high-sensitivity C-reactive protein(hs-CRP),and heart failure quality of life questionnaire(MLHFQ)scores in both groups of patients decreased after treatment,and the observation group was lower than the control group,with statistical significance(P＜0.05),tips for improving cardiac enzyme indicators and quality of life.The prognosis survey showed that the survival rate of patients in the observation group was higher than that in the control group,and the difference was statistically significant(P＜0.05).Conclusion Patients with valvular heart failure,active application of daglizin can significantly help patients improve heart-related indicators and improve the quality of life of patients.
Keywords：Heart failureDapagliflozinvalvular diseaseClinical efficacyObservational study
Publication Date：2024-11-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1306-1308,1313 )